Ligand Pharmaceuticals Incorpor

Historical 13F Holders

Symbol
LGND
CUSIP
53220K504
All holders as of
Q2 2026
Type
Equity
Class
COM NEW
Reported Value, Excluding Options
Total Filings

13D/G Filers

Investors who own more than 5% of a class must file a Schedule 13D or 13G. Every filing for 53220K504 since 12/18/2024, newest first.

Filer % of Class Filed
Invesco Ltd. 13G 6.1% 8/13/2026
Event 6/30/2026
Vanguard Portfolio Management LLC 13G 5.6% 5/1/2026
Event 3/31/2026
Vanguard Capital Management LLC 13G 5.0% 5/1/2026
Event 3/31/2026
Vanguard Group Inc 13G/A Amendment 11 0% 3/27/2026
Event 3/13/2026
Janus Henderson Group PLC 13G/A Amendment 9 5.3% 11/14/2025
Event 9/30/2025
BlackRock, Inc. 13G/A Amendment 18 14.5% 10/17/2025
Event 9/30/2025
Janus Henderson Group PLC 13G/A Amendment 8 5.5% 8/14/2025
Event 6/30/2025
Janus Henderson Group PLC 13G/A Amendment 7 5.3% 5/14/2025
Event 3/31/2025
Janus Henderson Group PLC 13G/A Amendment 6 5.4% 2/14/2025
Event 12/31/2024
BlackRock, Inc. 13G/A Amendment 17 15.6% 2/5/2025
Event 12/31/2024

13F Holders by Quarter

Period Filings Shares, Excl. Options Value, Excl. Options
2026 Q3 14 679 k $212 M
2026 Q2 434 29.6 M $7.18 B
2026 Q1 368 20.8 M $4.15 B
2025 Q4 359 20.6 M $3.89 B
2025 Q3 322 20.6 M $3.64 B
2025 Q2 277 19.2 M $2.18 B
2025 Q1 271 18.7 M $1.97 B
2024 Q4 268 18.3 M $1.96 B
2024 Q3 254 18.2 M $1.82 B
2024 Q2 244 17.5 M $1.48 B
2024 Q1 233 17.1 M $1.25 B
2023 Q4 223 16.5 M $1.18 B
2023 Q3 206 15.8 M $947 M
2023 Q2 211 15.6 M $1.12 B
2023 Q1 222 15.0 M $1.10 B
2022 Q4 207 15.4 M $1.03 B
2022 Q3 215 16.1 M $1.39 B
2022 Q2 205 14.9 M $1.33 B
2022 Q1 220 15.6 M $1.76 B
2021 Q4 239 16.4 M $2.53 B
2021 Q3 221 16.4 M $2.29 B
2021 Q2 225 15.9 M $2.09 B
2021 Q1 246 15.4 M $2.35 B
2020 Q4 266 23.6 M $2.35 B
2020 Q3 276 23.0 M $2.19 B
2020 Q2 287 22.1 M $2.48 B
2020 Q1 283 23.3 M $1.69 B
2019 Q4 291 23.0 M $2.40 B
2019 Q3 302 23.3 M $2.32 B
2019 Q2 341 26.3 M $3.00 B
2019 Q1 363 26.1 M $3.29 B
2018 Q4 397 27.2 M $3.69 B
2018 Q3 413 24.8 M $6.78 B
2018 Q2 367 25.9 M $5.37 B
2018 Q1 343 25.2 M $4.16 B
2017 Q4 315 24.7 M $3.38 B
2017 Q3 307 24.6 M $3.35 B
2017 Q2 279 25.0 M $3.04 B
2017 Q1 278 24.7 M $2.62 B
2016 Q4 295 24.9 M $2.53 B
2016 Q3 280 24.8 M $2.53 B
2016 Q2 282 25.0 M $2.98 B
2016 Q1 265 26.1 M $2.82 B
2015 Q4 243 23.3 M $2.53 B
2015 Q3 217 23.2 M $2.01 B
2015 Q2 226 21.9 M $2.21 B
2015 Q1 196 22.5 M $1.73 B
2014 Q4 189 21.8 M $1.16 B
2014 Q3 188 22.1 M $1.04 B
2014 Q2 206 21.1 M $1.31 B
2014 Q1 201 20.8 M $1.40 B